Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q2 2022 · 10-Q
Revenue$10.00M$10.00M— vs Q2 2021 Net Income$414.00K$414.00KN/M vs Q2 2021 EPS Diluted$0.00$0.00N/M vs Q2 2021 Operating Income$384,322N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,449,329N/M Margins · derivedOperating margin3.8%
Net margin4.1%
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end